pre-IPO PHARMA

COMPANY OVERVIEW

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.


LOCATION

  • Falmer, Brighton, UK

  • THERAPEUTIC AREAS

  • Respiratory Disease

  • WEBSITE

    https://www.enterprisetherapeutics.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    epidarex-capital forbion ip-group life-science-partners novartis-venture-fund versant-ventures


    PRESS RELEASES


    Jun 14, 2021

    Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001


    Jun 14, 2021

    Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001


    Oct 7, 2020

    Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche


    Oct 7, 2020

    Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche


    Aug 17, 2020

    Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002


    For More Press Releases


    Google Analytics Alternative